Newspaper Advertisement of Financial Results under regulation 47 of SEBI. (LODR)
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Transgene Biotek has submitted newspaper clippings of its unaudited financial results for the quarter ended June 30, 2025, as required under SEBI Regulation 47. The results were published in Business Standard (English) and Navatelangana (Telugu) on August 9, 2025, with Board approval dated August 8, 2025. The filing is signed by Managing Director Dr K Koteswara Rao. The document attached contains a mix of clippings, including clearly labelled Q1 FY26 results of Palred Technologies Limited and Telugu-language content referencing commodity-related figures (in metric tons), making Transgene Biotek's own standalone numbers not clearly discernible in the shared text.
This is a routine compliance filing confirming the company has published its Q1 FY26 results in newspapers as mandated. No material new information or strategy change is signalled, so expect neutral impact on the stock.